Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

It is vital for sponsors to reduce the burden on the site if they also want to lessen the strain on patients, said Shantheri ...